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1. Introduction 
Bromocriptine, an ergot alkaloid and dopamine 
agonist, is the treatment of choice for the induction 
of ovulation and pregnancy in cases of infertility due 
to both functional and organic hyperprolactinemia, 
the latter being due to prolactin secreting pituitary 
adenomas. It was found that 5-22% of the popula- 
tion harbour pituitary adenomas [ 1,2]. Bromocrip- 
tine has also been useful in the treatment of the symp- 
tomatic enlargement of pituitary adenomas during 
pregnancy as documented by tumor size reduction 
131. 
Bromocriptine crosses the placenta and enters the 
fetal circulation reducing prolactin secretion in both 
maternal and fetal pituitaries [4]. At the level of the 
pituitary lactotroph there is evidence of the existence 
of dopamine receptors on the cell membrane and that 
bromocriptine acts as a dopamine receptor agonist 
[S]. It has been suggested that bromocriptine acts 
primarily on prolactin secretion, and that the subse- 
quent accumulation of prolactin within the pituitary 
inhibits translation and possibly transcription, by an 
intracellular negative-feedback mechanism [6]. The 
results of our investigation indicate that bromocrip- 
tine itself may act by inhibiting transcription. 
2. Materials and methods 
L-[4,5-3H]Leucine (spec. act. 30.2 Ci/mmol and 
[5,6-3H]uridine (spec. act. 40.3 Ci/mmol) were pur- 
chased from Kamag, Negev. [‘*‘I] Iodine (carrier free) 
was purchased from Radiochemical Centre,Amersham. 
Rat prolactin and corresponding antiserum were sup- 
plied by the NlAMDD hormone distributors program 
ElsevierlNorth-Holland Biomedical Press 
(Dr Parlow). Bromocriptine (CB-154) was kindly 
donated by Sandoz, Switzerland. 
Pituitaries were surgically removed from 200 f 20 g 
Sabra strain female rats and bisected. Each hemi- 
pituitary was incubated in Krebs-Ringer-bicar- 
bonate buffer at 37’C with 10 PCi [3H]leucine or 
15 &i [3H]uridine with or without bromocriptine 
(3 X lo-’ M). At each time indicated, the tissue was 
separated from the medium, homogenized in 0.25 M 
sucrose TKM buffer (Tris-HCl @H 7.4) 50 mM; KC1 
25 mM; MgC12 10 mM) and spun in the presence of 
1% Triton X-l 00; 1% deoxycholate mixture at 
1000 X g for 20 min. The supernatants (tissue) and 
the media were analyzed. 
The incorporation of radioactive tracer was mea- 
sured as in [ 151. Protein content was determined as in 
[ 161. Prolactin radioimmunoassay was done according 
to the protocol supplied by the NIAMDD hormone 
distributors program. SDS gel electrophoresis was done 
as in [lo]. 
Samples were run on a 15% polyacrylamide SDS 
gel. Prolactin bands were identified, excised and dis- 
solved in H202: SDS (24%:2%) 1: 1 (v/v) and counted 
in aliquid scintillation counter. Isolation of poly [A(-)] 
and poly [A(t)] RNA was done as in [8]. 
3. Results and discussion 
Fig.1 shows the effect of bromocriptine on the syn- 
thesis (fig.1 A) and secretion (fig.1 B) of radioactive pro- 
teins by the rat hemipituitaries. 
At 3 X lo-’ M, bromocriptine causes a 50% inhibi- 
tion of incorporation of leucine into total protein from 
the first hour (whereas a dosage of 1 X lo-’ M gives to 
a 20% inhibition of synthesis and secretion of radioac- 
tive proteins,illustrating a clear dose-response effect). 
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Fig.]. The effect of bromocriptine on the incorporation of 
[3H]leucine into total tissue proteins (A), and on the secre- 
tion of radioactive proteins into the medium (B): control 
($A); bromocripttie (4,0). 
Up to 5 h, there is no secretion of radioactive pro- 
teins into the medium. At 5-6 h, the control hemipi- 
tuitaries begin to secrete radioactive proteins in a 
nearly linear mode. From 6-8 h, secretion occurs in 
bromocriptine-treated hemipituitaries at the same rate 
as in the controls, but after 9 h, 50% inhibition of 
secretion of radioactive proteins is visible in the medium 
of treated pituitaries. The effect of bromocriptine on 
the synthesis and secretion of newly synthesized pro- 
Iactin was investigated (fig.2). 
In the tissue of the control hemipituitaries the syn- 
thesis of radioactive prolactin increases steadily up to 
6 h, when a sharp acceleration in synthesis is evident. 
In the bromocriptine-treated tissue, inhibition is ap- 
parent from 1 h, reaching a maximum of 70% at 
10 h incubation. The first molecules of radioactive 
prolactin do not appear in the medium of the control 
hemipituitaries until after 6 h, since this is the time 
period required for the synthesis, transport and pack- 
aging of the hormone prior to secretion [7]. Although 
A 
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Fig.2. The effect of bromocriptine on the incorporation of 
[‘HI leucine into tissue prolactin (A) and secreted labelled 
prolactin (B): control (qn); bromocriptine (+A), 
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total inhibition of synthesis does not occur in the tis- 
sue, in the medium, bromocriptine halts completely 
the secretion of the de novo synthesized prolactin. 
Double antibody radioimmunoassay of the total pro- 
lactin content in both the tissue and the medium 
showed that in the tissue there was a sharp decrease 
in the amount of prolactin present in the first 2 h and 
this was accompanied by a corresponding increase in 
the medium. At zero time, no prolactin was measured 
in the medium, and no prolactin band was present in 
the gel. 
These observations led us to conclude that bromo- 
criptine had no effect on the secretion of the pre- 
existing pool of prolactin, and only acted on the newly 
synthesized hormone. 
With these results,it became necessary to investigate 
the possible effects of the drug on RNA synthesis, to 
determine whether transcription or translation was 
the primary site of action. 
Fig.3 shows the effect of bromocriptine on the in- 
corporation of uridine into RNA. In the untreated con- 
trol hemipituitaries, RNA synthesis begins immedi- 
ately, increasing gradually up to 8 h, where a sharp 
acceleration of the rate of synthesis is evident. 
In bromocriptine treated hemipituitaries,inhibition 
of synthesis is seen from 1 h until the end of the incu- 
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Fig.3. The effect of bromocriptine on the incorporation of 
[sH]uridine into total RNA: control (+); bromocriptine (A). 
Table 1 
The effect of bromocriptine on poly[A(-)] and poly[A(+)] 
RNA synthesis 
- 
Poly [A(-)] RNA Poly [A(+)] RNA 
(A) Control 10 300 5400 
Bromocriptine 1670 1640 
(B) Control, 4 h 35 400 116400 
Bromocriptine 
4h 14 700 19 300 
Poly [A(-)] and poly [A(+)] RNA fractions were isolated as 
in [ 81. (A) Hemipituitaries were incubated for 10 h in the pTeS- 
ence of 15 MCi [3H]uridine/sample. All samples were pooled 
and subjected for isolation of RNA. (B) Hemipituitaries were 
incubated for 4 h, then treated as above. Incubation medium 
contained 20 &i [3H] uridine/sample. The results are expressed 
as cpm/&, units isolated RNA. 
bation, where amaximum of BO%inhibition is reached. 
No radioactivity was detected in the medium, demon- 
strating the integrity of the tissue during the incuba- 
tion. 
All the samples represented in fig.3 were pooled and 
passed over a column of oligo(dT)-cellulose [8], in 
order to determine whether the inhibition was mRNA- 
specific or affected total RNA synthesis. In the poly- 
[A(-)] RNA, 84% inhibition was found, while 70% 
inhibition was seen in the poly[A(+)] RNA fraction 
(table 1). Hemipituitaries were incubated in the pres- 
ence of labeled uridine and the RNA was isolated after 
4 h. Inhibition of 60% was found in the poly[A(-)] 
RNA and inhibition of 85% in the poly [A(+)] RNA 
fraction. It should be noted that the total amounts 
of RNA present in the controls and the bromocrip- 
tine-treated tissue were approximately equal, which 
shows that the results were due to a specific inhibi- 
tion of RNA synthesis, and not due to RNase activity. 
In order to prove that the poly [A(+)] RNA was in 
fact mRNA, the isolated fraction was translated in a 
reticulocyte lysate cell free system [9]. 
The translation products were run on a SDS- 
polyacrylamide gel [IO] and autoradiographed, and 
since a major band present co-migrated with an ‘*‘I- 
labeled prolactin marker, and had app. MT 22 000, a 
further sample of the translation product was immu- 
noprecipitated with prolactin specific antiserum, rerun 
on the gel and autoradiographed (fig.4). Only one band 
was present and co-migrated with the iodinated stan- 
dard prolactin marker. 
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Fig.4. Autoradiogram of translation products in a reticulocyte 
lysate cell free system: (1) 1251-labeled prolactin marker; (2) 
translation prodUctS; (3) immunoprecipitate of translation 
products. 
Thus, bromocriptine in this system acts only on the 
secretion of de novo syn~esized.prola~tin in the hemi- 
pituitary and not on the preexisting pool. Serum pro- 
lactin takes l-3 days to reach normal levels when 
using bromocriptine in hyperprolactinemic patients 
t111. 
Bromocriptine inhibition is much more profound 
in the poly [A(t)] RNA synthesis (85%) than in pro- 
tein synthesis (50%) which lends support to the idea 
that transc~ption is the primary site of action. 
This may explain why bromocriptine is so effective 
where there is a large production of mRNA in pituitary 
cells as in the hyperprolactine~~ state during preg- 
nancy, or in prolactin secreting adenomas (especially 
when they are active during pregnancy). This effect of 
bromocriptine on mRNA may also explain the capac- 
ity of bromocrip~ne to reduce the tumor size of pitu- 
itary adenomas [ 121. Bromocriptine specifically in- 
hibits prolactin synthesis and secretion and to a lesser 
degree other pituitary hormones such as growth hor- 
mone. It is known that the effect of bromocriptine in 
patients with growth hormone secreting pituitary 
adenomas is less effective than with prolactin secreting 
adenomas [ 131, or in the mixed type of adenoma [ 14 J. 
From these results, we propose that the primary 
effect of bromocriptine is on the transcriptional level. 
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